Abstract The 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal
Implantable Cardioverter-Defibrillator Programming and Testing provided guidance on …

The 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal
Implantable Cardioverter-Defibrillator Programming and Testing provided guidance on …

Implantable cardioverter-defibrillator (ICD) therapy is clearly an effective therapy for selected
patients in definable populations. The benefits and risks of ICD therapy are directly impacted …

Background Inappropriate therapy is a common adverse effect in patients with an
implantable cardioverter–defibrillator (ICD) that may be prevented by appropriate …

Background—Patients who receive implantable cardioverter defibrillator therapies are at
higher risk of death versus those who do not. Programmed settings to reduce nonessential …

(ICDs) play a crucial role in the treatment of patients at heightened risk of sudden cardiac
death (SCD) caused by ventricular arrhythmias. The use of ICDs for primary prevention is …

Implantable cardioverter‐defibrillators (ICDs) improve survival when used as primary or
secondary prevention therapy in patients with a broad spectrum of disorders associated with …

Implantable cardioverter-defibrillators (ICDs) are generally reliable medical devices that
have the potential to add quality years of life for appropriate candidates. Indications for ICDs …

Implantable cardioverter-defibrillators (ICDs) reduce sudden cardiac death risk and improve
survival in patients with a history of life-threatening arrhythmia or cardiac arrest (secondary …

Despite the demonstrated efficacy of implantable cardioverter defibrillators (ICDs) in
reducing sudden and total mortality in selected patients, their implantation rates vary greatly …